Phase 2 Alopecia Areata Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are a man or woman aged 18 or older.
• You are able to understand the study and are willing to sign a consent form before taking part.
• You are able to attend scheduled appointments and follow the study requirements.
• If you are a woman who could become pregnant, you must have a negative pregnancy test before starting and agree to use effective contraception during the study and for at least 28 days after the last dose.
• If you are a woman who cannot become pregnant, you have documentation of infertility, have been through menopause for at least one year, or have had a hysterectomy or surgery to remove both ovaries or fallopian tubes.
• You have had moderate to severe alopecia areata (hair loss covering at least 50% of the scalp) for at least 6 months, or you have lost 95% or more of your scalp hair (total or universal hair loss).
• You have a blood test result showing a certain immune marker (IgE) above 200, and/or you or a close family member have a history of allergic conditions such as hay fever, eczema, or asthma.
• Your blood test results fall within specific acceptable ranges for white blood cells, platelets, kidney function, liver function, and red blood cells (confirm with trial site for exact values).
• You are considered to be in generally good health based on your medical history, a physical examination, and blood tests.

Who may not be able to join:

• You are currently pregnant or breastfeeding.
• Your hair loss has more than one cause, or the cause is unclear — for example, hair loss due to pulling, scarring, pregnancy, medication, stress-related shedding, or advanced pattern baldness.
• You have had alopecia areata with no signs of any hair regrowth for 7 or more years since your last episode of hair loss.
• You have severe, uncontrolled asthma or have had a life-threatening asthma attack even while on appropriate asthma medication.
• You currently have an active bacterial, viral, or parasitic infection, or you have a history of frequent serious infections that required treatment with antibiotics given into a vein or by mouth.
• You have a known or suspected problem with your immune system that leaves you unable to fight infections normally.
• You have a serious, ongoing, or hard-to-control condition affecting your kidneys, liver, blood, gut, metabolism, hormones, lungs, heart, or nervous system.
• You have active hepatitis B, hepatitis C, HIV, or untreated latent (inactive) tuberculosis (confirm with trial site regarding testing requirements).
• You have or are suspected to have a blood cancer or lymph gland disorder, or you have had any cancer in the past 5 years — with the exception of certain fully treated skin cancers or cervical cancer that has not spread.
• You received a live vaccine (such as MMR or chickenpox) within 30 days before joining the study.
• You have unusual or significant abnormal blood test results that could affect how study results are interpreted.
• You have any other medical or mental health condition that the study doctor believes could put you at extra risk or prevent you from completing the study visits.
• You have previously had a serious allergic or harmful reaction to any ingredient in the study drug.
• You have used certain immune-suppressing medicines (such as cyclosporine, methotrexate, azathioprine, or certain steroid treatments) or light therapy (UV phototherapy) within 4 weeks before joining the study.
• You have taken a JAK inhibitor tablet (such as tofacitinib, ruxolitinib, or baricitinib) within 12 weeks before your baseline visit.
• You have previously been treated with dupilumab.
• You have used steroid creams or certain other skin creams (tacrolimus or pimecrolimus) within 1 week before your baseline visit.
• You currently use or plan to use anti-retroviral (HIV) medication at any point during the study.

Important: Always verify eligibility with the trial site directly before applying.